Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17843286.2020.1727665 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Women's experience of premature ovarian insufficiency (POI) diagnosis: update on actual practices and women's follow-up (EMPOIHER Study).
Menopause
September 2025
Department of Gynaecology and Reproductive Medicine, Bordeaux University Hospital, Bordeaux, France.
Objective: Although premature ovarian insufficiency (POI) diagnosis can be devastating, few studies focused on women's experiences of the disclosure. The objective of EMPOIHER study was to evaluate women's satisfaction with POI disclosure and the association with subsequent adherence to the treatment plan and medical follow-up.
Methods: We studied a cohort of 101 women diagnosed with spontaneous POI who attended two French University Hospitals between 2017 and 2024.
Monkeypox: A comprehensive review with a focus on the Middle East and North Africa (MENA) region.
Qatar Med J
June 2025
Basrah Medical College, Basrah, Iraq *Email:
Monkeypox (Mpox) was identified as a virus endemic to Central and Western Africa. Since 2022, the virus has gained global attention due to increasing cases in non-endemic countries among patients having no link to travel to endemic areas. The virus is primarily transmitted through animal-to-human contact but has increasingly spread via human-to-human transmission.
View Article and Find Full Text PDFMay 2025 therapeutic delivery: industry update.
Ther Deliv
August 2025
School of Chemical and BioPharmaceutical Science, Technological University Dublin, Dublin 7, Ireland.
This month saw approvals for two products employing Halozyme's Enhanze drug delivery technology (BMS's Opdivo and Johnson and Johnson's DARZALEX FASPRO®). A number of collaborations between industry partners and charities to fight the disease, including Duchenne muscular dystrophy and Epidermolysis Bullosa, have been announced. Successful clinical trial data was disclosed for products employing a wide variety of therapeutic delivery technologies including Perfuse Therapeutics intravitreal implant for glaucoma, Aspen Neurosciences precision delivery of an autologous dopaminergic neuronal precursor cell therapy for Parkinson's disease and Resurge Therapeutics IntraProstatic Drug Elution (IPDE) therapy for prostate cancer.
View Article and Find Full Text PDFFrom radiation beams to digital streams: social media engagement of German radiotherapy facilities.
Strahlenther Onkol
July 2025
Department of Radiotherapy, Wilhelm-Conrad-Roentgen-Clinic, University Hospital Giessen-Marburg, Giessen, Germany.
Purpose: Social media (SoMe) increasingly impacts communication in the healthcare sector. Despite its growing relevance, there is limited research on how these institutions utilize SoMe for their purposes. We conducted a descriptive analysis with the aim of evaluating the presence, frequency, and content focus of SoMe activities of German radiotherapy institutions.
View Article and Find Full Text PDFDonanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia.
Australas Psychiatry
August 2025
Neuropsychiatry Centre, Royal Melbourne Hospital, Parkville, VIC, Australia.
On 22 May 2025, the Therapeutic Goods Administration (TGA) announced that the anti-amyloid monoclonal antibody donanemab (Eli Lilly, Kisunla) was approved in Australia for the treatment of Alzheimer's disease (AD). This has been heralded by some as a breakthrough for the treatment of AD, reflecting a turning point from symptomatic treatments to disease-modifying therapies. Psychiatrists should understand this scientific context, as it underpins both the hope and the limits of what donanemab can achieve.
View Article and Find Full Text PDF